PMC:2944646 / 37441-38136 JSONTXT

{"project":"TEST0","denotations":[{"id":"20877425-134-142-198983","span":{"begin":321,"end":325},"obj":"[\"12006732\"]"},{"id":"20877425-141-149-198984","span":{"begin":518,"end":522},"obj":"[\"8437693\"]"}],"text":"Only few studies have been conducted in specific groups of patients with either Alzheimer type or vascular dementia. In most studies, mixed groups of demented patients were investigated. Nevertheless, cognitive improvement was seen under the treatment with piracetam regardless of the type of dementia (Waegemans et al., 2002). Most of these studies however were rather short. In the only one 1-year trial in AD patients, some evidence for a reduction of the cognitive decline over time was detected (Croisile et al., 1993), were the MMSE (minimental state evaluation did not change significantly in the Piracetam group but showed the expected 3 point decline in the placebo group over the year."}

{"project":"0_colil","denotations":[{"id":"20877425-12006732-198983","span":{"begin":321,"end":325},"obj":"12006732"},{"id":"20877425-8437693-198984","span":{"begin":518,"end":522},"obj":"8437693"}],"text":"Only few studies have been conducted in specific groups of patients with either Alzheimer type or vascular dementia. In most studies, mixed groups of demented patients were investigated. Nevertheless, cognitive improvement was seen under the treatment with piracetam regardless of the type of dementia (Waegemans et al., 2002). Most of these studies however were rather short. In the only one 1-year trial in AD patients, some evidence for a reduction of the cognitive decline over time was detected (Croisile et al., 1993), were the MMSE (minimental state evaluation did not change significantly in the Piracetam group but showed the expected 3 point decline in the placebo group over the year."}

{"project":"2_test","denotations":[{"id":"20877425-12006732-38148076","span":{"begin":321,"end":325},"obj":"12006732"},{"id":"20877425-8437693-38148077","span":{"begin":518,"end":522},"obj":"8437693"}],"text":"Only few studies have been conducted in specific groups of patients with either Alzheimer type or vascular dementia. In most studies, mixed groups of demented patients were investigated. Nevertheless, cognitive improvement was seen under the treatment with piracetam regardless of the type of dementia (Waegemans et al., 2002). Most of these studies however were rather short. In the only one 1-year trial in AD patients, some evidence for a reduction of the cognitive decline over time was detected (Croisile et al., 1993), were the MMSE (minimental state evaluation did not change significantly in the Piracetam group but showed the expected 3 point decline in the placebo group over the year."}